Antihyperglycemic therapy in patients with type 2 diabetes mellitus and ischaemic heart disease: management during acute period of myocardial infarction and interventional procedures
https://doi.org/10.14341/2072-0351-6083
Abstract
Current paper presents data from international multicenter studies performed with participation of patients with type 2 diabetes mellitus(T2DM) and ischaemic heart disease. We analyze results regarding advisability of different glycemic targets, prescription safetyof various classes of antihyperglycemic agents in patients with inschaemic heart disease, acute coronary syndrome and chronic heartfailure, as well as therapeutic approach to glycemic control in acute myocardial infarction and cardiologic interventional procedures.
About the Authors
Olga Mikhailovna Smirnova
Endocrinology Research Centre, Moscow
Irina Vladimirovna Kononenko
Endocrinology Research Centre, Moscow
References
1. Morrish NJ, Wang SL, StevensLK, Fuller JH, Keen H. Mortality and causes of death in the WHO Multinational Study of Vascular Diease in Diabetes. Diabetologia. 2001 Sep;44 Suppl 2:S14-21.
2. Stone PH, Muller JE, Hartwell T, York BJ, Rutherford JD, Parker CB, Turi ZG, Strauss HW, Willerson JT, Robertson T, et al. The effect of diabetes mellitus on prognosis and serial left ventricular function after acute myocardial infarction: contribution of both coronary disease and left ventricular dysfunction to the adverse prognosis. The MILIS Study Group. J Am Coll Cardiol. 1989 Jul;14(1):49-57.
3. Herlitz J, Maimberg K, Karlson BW, Ryden L, Hjalmarson A. Mortality and morbidity during a five-year follow-up of diabetics with myocardial infarction. Acta Med Scand. 1988;224(1):31-38.
4. Granger CB, Califf RM, Young S, Candela R, Samaha J, Worley S, Kereiakes DJ, Topol EJ.Outcome of patients with diabetes mellitus and acute myocardial infarction treated with thrombolytic agents. The Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group. J Am Coll Cardiol. 1993 Mar 15;21(4):920-925.
5. Rydén L, Standl E, Bartnik M, Van den Berghe G, Betteridge J, de Boer MJ, Cosentino F, Jönsson B, Laakso M, Malmberg K, Priori S, Ostergren J, Tuomilehto J, Thrainsdottir I, Vanhorebeek I, Stramba-Badiale M, Lindgren P, Qiao Q, Priori SG, Blanc JJ, Budaj A, Camm J, Dean V, Deckers J, Dickstein K, Lekakis J, McGregor K, Metra M, Morais J, Osterspey A, Tamargo J, Zamorano JL, Deckers JW, Bertrand M, Charbonnel B, Erdmann E, Ferrannini E, Flyvbjerg A, Gohlke H, Juanatey JR, Graham I, Monteiro PF, Parhofer K, Pyörälä K, Raz I, Schernthaner G, Volpe M, Wood D; Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC); European Association for the Study of Diabetes (EASD). Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J. 2007 Jan;28(1):88-136.
6. Colagiuri S. Optimal management of type 2 diabetes: the evidence. Diabetes Obes Metab. 2012 Jan;14 Suppl 1:3-8. doi: 10.1111/j.1463-1326.2011.01506.x.
7. United Kingdom Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33). Lancet. 1998 Sep 12;352(9131):837-853.
8. Bennett WL, Maruthur NM, Singh S, Segal JB, Wilson LM, Chatterjee R, Marinopoulos SS, Puhan MA, Ranasinghe P, Block L, Nicholson WK, Hutfless S, Bass EB, Bolen S.Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. Ann Intern Med. 2011 May 3;154(9):602-613. Epub 2011 Mar 14.
9. Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M, Lafont S, Bergeonneau C, Kassaï B, Erpeldinger S, Wright JM, Gueyffier F, Cornu C. Effect of intensive glucose liwering treatment on all cause mortality, cardiovascular death, and microvascular event in type 2 diabetes: meta-analysis of randomized controlled trials. BMJ 2011; Jul 26; 343:d4169 doi: 10.1136/bmj.d4169.
10. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR; American Diabetes Association (ADA); European Association for the Study of Diabetes (EASD). Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach. Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012 Jun;35(6):1364-1379. Epub 2012 Apr 19.
11. Дедов ИИ, Шестакова МВ, Аметов АС, Анциферов МБ, Гал- стян ГР, Майоров АЮ, Мкртумян АМ, Петунина НА, Сухарева ОЮ. Проект «Консенсус совет экспертов Российской ассоциации эндокринологов (РАЭ) по инициации и интенсификации сахароснижающей терапии СД 2 типа». Сахарный диабет. 2011;(1): 95-105.
12. Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M, Lafont S, Bergeonneau C, Kassaï B, Erpeldinger S, Wright JM, Gueyffier F, Cornu C. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabrtrs: meta-analysis of randomized controlled trials. BMJ. 2011 Jul 26;343:d4169. doi: 10.1136/bmj.d4169.
13. Kelly TN, Bazzano LA, Fonseca VA, Thethi TK, Reynolds K, He J. Systematic Review: Glucose Control and Cardiovascular Disease in Type 2 diabetes Ann Intern Med. 2009 Sep 15;151(6):394-403. Epub 2009 Jul 20.
14. Desouza CV, Bolli GB, Fonseca V. Hypoglycemia, Diabetes, and Cardiovascular Events. Diabetes Care. 2010 Jun;33(6):1389-1394.
15. Jackson RA, Hawa MI, Jaspan JB, Sim BM, Disilvio L, Featherbe D, Kurtz AB. Mechanism of metformin action in non-insulindependent diabetes. Diabetes. 1987 May;36(5):632-640.
16. Cusi K, Consoli A, DeFronzo RA. Metabolic effects of metformin on glucose and lactate metabolism in noninsulindependent diabetes mellitus. J Clin Endocrinol Metab. 1996 Nov;81(11):4059-4067.
17. Salpeter S, Greyber E, Pasternak G, Salpeter E. Risk of fatal and nonfatal acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev. 2006 Jan 25;(1):CD002967.
18. Eurich DT, Majumdar SR, McAlister FA, Tsuyuki RT, Johnson JA. Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. Diabetes Care. 2005 Oct;28(10):2345-2351.
19. Evans JM, Doney AS, AlZadjali MA, Ogston SA, Petrie JR, Morris AD, Struthers AD, Wong AK, Lang CC. Effect of metformin on mortality in patient with heart failure and type 2 diabetes mellitus. Am J Cardiol. 2010 Oct 1;106(7):1006-1010.
20. Полторак ВВ, Горбенко НИ, Горшунская МЮ. Блокада КATP каналов препаратами сульфонилмочевины и кардиоваску- лярная безопасность у больных сахарным диабетом 2 типа. Украинский медицинский вестник. 2002;(6): 65-78.
21. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation. 1986 Nov;74(5):1124-1136.
22. Miki T, Seino S. Roles of KATP channels as metabolic sensors in acute metabolic changes. J Mol Cell Cardiol. 2005 Jun;38(6):917-925. Epub 2005 Feb 5.
23. Johnsen SP, Monster TB, Olsen ML, Thisted H, McLaughlin JK, Sørensen HT, Lervang HH, Rungby J. Risk and short-term prognosis of myocardial infarction among users of antidiabetic drugs. Am J Ther. 2006 Mar-Apr;13(2):134-140.
24. Schramm TK, Gislason GH, Vaag A, Rasmussen JN, Folke F, Hansen ML, Fosbøl EL, Køber L, Norgaard ML, Madsen M, Hansen PR, Torp-Pedersen C. Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. Eur Heart J. 2011 Aug;32(15):1900-1908. Epub 2011 Apr 6.
25. Викулова ОК, Шестакова МВ. Терапия глибенкламидом: за или против? Сахарный диабет. 2011;(3):92-95.
26. Khalangot M, Tronko M, Kravchenko V, Kovtun V. Glibenclamide- related excess in total and cardiovascular mortality risks: data from large Ukrainian observational cohort study. Diabetes Res Clin Pract. 2009 Dec;86(3):247-253. Epub 2009 Sep 30.
27. Deedwania P, Kosiborod M, Barrett E, Ceriello A, Isley W, Mazzone T, Raskin P. Hyperglycemia and Acute Coronary Syndrome: A Scientific Statement From the American Heart Association Diabetes Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation 2008; 117; 1610-1619; Anesthesiology. 2008 Jul;109(1):14-24.
28. Anantharaman R, Heatley M, Weston CF. Hyperglycaemia in acute coronary syndromes: risk-marker or therapeutic target? Heart. 2009 May;95(9):697-703. Epub 2008 Aug 12.
29. Malmberg K, Rydén L, Efendic S, Herlitz J, Nicol P, Waldenström A, Wedel H, Welin L. Randomised trail of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetes patients with acute myocardial infarction (DIGAMI Study): effects on mortality at 1 year. J Am Coll Cardiol. 1995 Jul;26(1):57-65.
30. Malmberg K, Rydén L, Wedel H, Birkeland K, Bootsma A, Dickstein K, Efendic S, Fisher M, Hamsten A, Herlitz J, Hildebrandt P, MacLeod K, Laakso M, Torp-Pedersen C, Waldenström A; DIGAMI 2 Investigators. Intens metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. Eur Heart J. 2005 Apr;26(7):650-661. Epub 2005 Feb 23.
31. Cheung NW, Wong VW, McLean M. The Hyperglycemia: Intensive Insulin Infusion In Infarction (HI-5) Study: A randomized controlled trial of insulin infusion therapy for myocardial infarction. Diabetes Care. 2006 Apr;29(4):765-770.
32. Díaz R, Goyal A, Mehta SR, Afzal R, Xavier D, Pais P, Chrolavicius S, Zhu J, Kazmi K, Liu L, Budaj A, Zubaid M, Avezum A, Ruda M, Yusuf S. Glucose-insulin-potassium therapy in patients with ST-segment elevation myocardial infarction. JAMA. 2007 Nov 28;298(20):2399-2405.
33. Vergès B, Avignon A, Bonnet F, Catargi B, Cattan S, Cosson E, Ducrocq G, Elbaz M, Fredenrich A, Gourdy P, Henry P, Lairez O, Leguerrier AM, Monpère C, Moulin P, Vergès- Patois B, Roussel R, Steg G, Valensi P; Diabetes and Cardiovascular Disease study group of the Société francophone du diabète (SFD), in collaboration with the Société française de cardiologie (SFC). Consensus statement on the care of the hyperglycaemic/diabetic patient during and in the immediate follow-up of acute coronary syndrome. Diabetes Metab. 2012 Apr;38(2):113-127. Epub 2011 Dec 30.
34. Acute myocardial infarction: pre-hospital and in-hospital management. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J. 1996 Jan;17(1):43-63.
35. Дедов ИИ, Шестакова МВ, Александров АнА, Галстян ГР, Григорян ОР, Эсаян РМ, Калашников ВЮ, Кураева ТЛ, Липатов ДВ, Майоров АЮ, Петеркова ВА, Смирнова ОМ, Старостина ЕГ, Суркова ЕВ, Сухарева ОЮ, Токмакова АЮ, Шамхалова МШ, Ярек-Мартынова ИР. Алгоритмы специализированной медицинской помощи больным са- харным диабетом (5-й выпуск). Сахарный диабет. 2011;(3 прил.1):4-72.
Review
For citations:
Smirnova O.M., Kononenko I.V. Antihyperglycemic therapy in patients with type 2 diabetes mellitus and ischaemic heart disease: management during acute period of myocardial infarction and interventional procedures. Diabetes mellitus. 2012;15(3):27-38. (In Russ.) https://doi.org/10.14341/2072-0351-6083
Views:
5070
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
